A
A
A

Isomorphic Labs 宣布完成50亿美元C轮融资

·10 hours ago发布

LONDON, 17 November, 2026 - Isomorphic Labs, an AI company focussed on designingand developing new medicines, today announced a $5 Billion Series C financing round. Theround was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz(a16z) and several other new investors, with continued significant investment fromAlphabet. The round also included participation from all existing investors: Thrive Capital,MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. 

 

Isomorphic is scaling its proprietary drug design engine (IsoDDE) and therapeuticcandidate pipeline designed with AI to deliver the next generation of medicines. IsoDDEunifies a suite of foundational simulation AI models that natively work across multipletherapeutic areas and drug modalities. IsoDDE explores vast chemical spaces to enableIsomorphic’s world-class team to design, refine, and deliver exquisitely engineeredmolecules with optimal drug-like properties. 

 

The breadth and precision of the simulation models within IsoDDE push predictionstowards experimental accuracy and provide a suite of capabilities to advance innovativemedicines. Combined with powerful proprietary agents that navigate and reason overhighly complex biological systems, these models directly and repeatedly translate intoadvancements across the company's multi-modality pipeline of therapeutic candidates,addressing some of the most challenging problems in the industry. This momentum isyielding positive preclinical results, both for internal programs in oncology and immunologyand with partners, setting the stage for clinical entry.

 

This new capital accelerates the scientific breakthroughs and proprietary AI advancesbeing made by Isomorphic. The company will continue to mature IsoDDE as well as expanddeeper into new biology with highly advanced models. To deliver new and transformativeclasses of therapeutics, Isomorphic is creating a partner ecosystem to advance theunderstanding of mechanistic disease biology. In parallel, the company is building theglobal infrastructure required to power the future of AI-led bioengineering. Proceeds willalso support the company’s continued build of scalable AI-first translational and clinicaldevelopment infrastructure as it advances its drug candidates to clinical trials.

 

"When we founded Isomorphic, our conviction was that biology could be understood andmodelled at the most fundamental molecular level and radically accelerated through AI,"said Sir Demis Hassabis, Founder and CEO of Isomorphic Labs. “Our drug design engineis generating molecules with unprecedented precision and speed. This round enables us toaccelerate our progress: building foundational biology models, deepening our systemicdisease understanding, and driving our first therapeutic programs towards clinical trials todeliver tangible impact for patients."

 

"Every week we are making repeatable scientific advancements enabled by our models,"said Max Jaderberg, President of Isomorphic Labs. "These translate directly into bettermolecular profiles with the potential to be new medicines and unlock some of the hardestproblems in drug discovery. Our interdisciplinary teams combine world-leading machinelearning researchers with top-class drug hunters and together they are routinely solvingcomplex biological problems that have stalled traditional research for decades. We aretranslating our discoveries directly into potential life-changing medicines, built on theinfrastructure we are establishing for the future of bioengineering with this investorbacking."

 

"Discovering and developing new medicines is an optimization challenge of almost infinitescale," said Neil Mehta, Founder and Managing Partner of Greenoaks. "Isomorphic istransforming that journey, building deep learning systems that can predict complexbiological behaviors with remarkable accuracy and systematically map the path to newmedicines. We believe Demis, Max, and the Isomorphic team are building the future of AIled drug discovery and we are proud to partner with them on this essential mission." 

 

“Isomorphic Labs is building foundational technology for the future of medicine,” saidKonstantine Buhler, Partner at Sequoia Capital. “It’s inspiring to see the Isomorphic teamtranslate advanced AI into a growing portfolio of drug candidates. Using AI to improvehuman health is one of the most important challenges of our generation. We’re proud toco-lead this round and help further scientific discovery in medicine.”

 

ABOUT ISOMORPHIC LABS 

 

Isomorphic Labs was founded in 2021, to transform drug discovery withthe power of artificial intelligence, ushering in a new era of biomedicalbreakthroughs. Isomorphic Labs is led by CEO Sir Demis Hassabis andPresident Max Jaderberg. Isomorphic Labs has built a world-leading AIdrug design engine comprising foundational AI models that are capableof working across multiple therapeutic areas and drug modalities. Thecompany is continually innovating on model architecture anddeveloping cutting-edge capabilities to advance drug design.

 

Isomorphic Labs is headquartered in London and has office locations inCambridge, Massachusetts and Lausanne, Switzerland. IsomorphicLabs is advancing a broad and ambitious drug design portfolio throughpartnered programs and wholly-owned internal programs.

文章关键词: Isomorphic Labs50亿美元C轮融资
下载PDF
0
发布文章
0
关注人数